Renaissance Technologies LLC Grows Holdings in Lantern Pharma Inc. (NASDAQ:LTRN)

Renaissance Technologies LLC increased its holdings in shares of Lantern Pharma Inc. (NASDAQ:LTRN) by 24.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,800 shares of the company’s stock after acquiring an additional 16,100 shares during the period. Renaissance Technologies LLC owned approximately 0.76% of Lantern Pharma worth $382,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Dimensional Fund Advisors LP grew its stake in shares of Lantern Pharma by 55.7% in the second quarter. Dimensional Fund Advisors LP now owns 18,413 shares of the company’s stock worth $86,000 after acquiring an additional 6,585 shares during the last quarter. CM Management LLC lifted its holdings in shares of Lantern Pharma by 23.1% during the second quarter. CM Management LLC now owns 80,000 shares of the company’s stock valued at $374,000 after purchasing an additional 15,000 shares in the last quarter. Westside Investment Management Inc. purchased a new stake in shares of Lantern Pharma during the second quarter valued at $54,000. Finally, Tocqueville Asset Management L.P. purchased a new stake in shares of Lantern Pharma during the first quarter valued at $167,000. Hedge funds and other institutional investors own 28.62% of the company’s stock.

Lantern Pharma Stock Down 4.0 %

Shares of LTRN stock opened at $3.39 on Friday. The firm has a market capitalization of $36.47 million, a PE ratio of -2.03 and a beta of 1.55. The company has a 50 day moving average price of $3.92 and a 200-day moving average price of $5.14. Lantern Pharma Inc. has a 52 week low of $2.38 and a 52 week high of $11.99.

Lantern Pharma (NASDAQ:LTRN) last announced its earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.09. During the same quarter in the previous year, the business earned ($0.44) EPS. Analysts anticipate that Lantern Pharma Inc. will post -2.12 earnings per share for the current year.

Lantern Pharma Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.